Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 16/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23747170 | 0.95 | EPHA2 (0.41) | EPHA2KDREPHB4BRAFEGFR | |
| SCHEMBL23747232 | 0.92 | EGFR (0.47) | EPHA2KDREPHB4BRAFEGFR | |
| SCHEMBL26428660 | 0.88 | EGFR (0.43) | BRAFEGFRERBB2MAPT | |
| SCHEMBL23747231 | 0.88 | ERBB2 (0.49) | EGFRERBB2 | |
| SCHEMBL23747254 | 0.84 | ERBB2 (0.42) | EPHA2KDREPHB4BRAFEGFR | |
| SCHEMBL23957472 | 0.84 | ERBB2 (0.44) | BRAFEGFRERBB2MAPT | |
| SCHEMBL30613043 | 0.84 | BRAF (0.47) | BRAFEGFRERBB2 | |
| SCHEMBL26428661 | 0.84 | EGFR (0.41) | BRAFEGFRERBB2MAPT | |
| SCHEMBL31193378 | 0.84 | BRAF (0.47) | BRAFEGFRERBB2 | |
| SCHEMBL23750186 | 0.84 | EGFR (0.54) | EPHA2KDREPHB4BRAFEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131720-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT) | 2023-04-27 | — | — | US | disclosed |
| US-20230131720-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM RCV GMBH & CO KG (AT) | 2023-04-27 | — | — | US | disclosed |
| WO-2021156180-A1 | [1,3]DIAZINO[5,4-D]PYRIMIDINES AS HER2 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131720-A1 | [1,3]DIAZINO[5,4-d]PYRIMIDINES AS HER2 INHIBITORS | ERBB2, ERBB3, ERBB4 | EPHA2 193/4885KDR 48/4885EPHB4 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.